Factors influencing COVID-19 vaccine acceptability among household heads in northern Nigeria: a community-based cross-sectional study.

Objectives: COVID-19 vaccine was rolled out for the public in August 2021 in Zamfara state, Northen Nigeria. We determined the factors influencing COVID-19 vaccine acceptance.

Settings: We executed a community-based analytical cross-sectional study during the first 4 months of the second phase of the COVID-19 (Oxford/AstraZeneca) mass vaccination campaign in Zamfara state.

Charting the path to the implementation of universal health coverage policy in Nigeria through the lens of Delphi methodology.

Background: Expanding access to equitable health insurance is an important lever towards the overall strategy for achieving universal health coverage. In Nigeria, health insurance coverage is low with a renewed government action on increasing access to and coverage of high-quality healthcare services to citizens, particularly for the vulnerable and poor population. Therefore, our study co-creates the priorities for expanding health insurance in Nigeria, focusing on key policy reforms, public advocacy, and innovative financing strategies to ensure broader and more equitable coverage for the population.

Paternal Zinc Deficiency and Its Transgenerational Effects on Zinc Transporters in Drosophila.

The nutritional status of fathers plays a significant role in influencing the growth, metabolism, and susceptibility to diseases in their offspring. Paternal zinc deficiency can lead to developmental programming effects on the offspring's zinc homeostasis. This study investigated the effects of paternal zinc deficiency on the zinc homeostasis of offspring in a Drosophila melanogaster (fruit fly) model.

Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.

Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk estimation has not been performed.

Methods: We explored the distribution of PRS across European populations using genotype data from 94,072 females without breast cancer diagnosis, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 223,316 females without breast cancer diagnosis from the UK Biobank.